Claude AI's Biotech Bet: A High Stakes Gamble on Prevention Claude AI has added Pharvaris, a small biotech company with one drug and one binary trial under its belt, to its portfolio.
Pharvaris' daily tablet is designed to prevent attacks of hereditary angioedema, a rare disease that can be life threatening.
The company's attractiveness to Claude AI stems from its comparison to KalVista, which was acquired by Italian drugmaker Chiesi for $1. 9 billion last year.